Preview

February 2020

In the next issue of Pharma Technology Focus, we review the most successful projects to be funded by the EU’s Horizon 2020 scheme, dig through the fine print of the Lower Drug Costs Now Act to find out how the proposed legislation could impact the industry in the US, and talk the future of pharmacies and batch testing with Valisure.

Also, we explore the relationship between old age and drug development after the World Health Organization proposed classifying ageing as a condition, find out how ‘just-in-time’ medications that can be manufactured aboard space shuttles could help protect astronauts during deep space missions, and examine the comeback of Biogen’s Alzheimer’s treatment aducanumab.

Plus, we find out about Ehlers-Danlos syndromes and the treatments available to patients suffering with the condition, and take a look at pharma’s role in improving global access to medicines.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Abi Millar, Chris Lo, Chloe Kent, Natalie Healey
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova, Filipe Costa
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Pharma Technology Focus is a product of Net Resources International. Copyright 2020 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Access denied: the Impact trial Go to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: NewsGo to article: FargoGo to article: The pharma industry briefingGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Breast cancer timeline: charting three decades of successGo to article: PrEP drugs: is the NHS letting down patients at risk of HIV?Go to article: Swiss WorldCargoGo to article: Debate: can US pharma be taxed into behaving?Go to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Can new therapies tackle the burden of endometriosis?Go to article: The rise of fake medicines in AfricaGo to article: Zenatek Go to article: Off-the-shelf CAR-T therapy: broadening the reach of precision medicineGo to article: Nobel Prize 2019: how a breathtaking discovery unlocked new drugsGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: China in 2019: a prime destination for R&D deals Go to article: The global-local continuum: tips for a joined-up approach to Regulatory & PV outGo to article: Pharmacovigilance 2.0: reskilling for the digital & data science ageGo to article: Air France KLM Cargo Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue